Posted by Michael Wonder on 21 Jun 2023
Darolutamide in combination with androgen deprivation therapy and docetaxel for the treatment of patients with hormone-sensitive metastatic prostate cancer
21 June 2023 - NICE has published final evidence-based recommendations on the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy and docetaxel for the treatment of adults with hormone sensitive metastatic prostate cancer.
Darolutamide, when used in combination with docetaxel, is recommended for the treatment of adults with hormone sensitive metastatic prostate cancer.
